COMBINED APPROACH TO BROADLY PROTECTIVE AIDS VACCINES: PROJECT 4

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 我们曾报道过对不同的“初始-增强”免疫方案的保护效果的比较研究，包括用表达HIV-1 SF162 Env或SIVmac239Gag/Pol的重组疫苗或DNA载体启动，然后用DNA、蛋白质或表达相同抗原的异种病毒载体加强免疫。结果表明，无论是哪种免疫原，用蛋白疫苗加强免疫的动物具有显著更高的抗体效价，包括同源中和抗体(NtAb)。在SHIVSF162P4攻击后，所有免疫组的平均血浆病毒载量均显著降低。负相关(Spearman‘s r=-0.819)，比接种dna或病毒载体疫苗的动物少10倍。在直肠内SHIV162 P4攻击后，蛋白-DNA或蛋白-蛋白质数增强组中除一只动物外，其余动物均被感染。这些结果进一步支持了启动免疫在产生针对灵长类慢病毒感染的保护性免疫中的重要作用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We previously reported comparative studies of the protective efficacy of different "prime-boost" immunization regimens consisted of priming with recombinant vaccinia or DNA vectors expressing HIV-1 SF162 Env or SIVmac239 Gag/Pol, followed by boosting with DNA, protein; or heterologous viral vector expressing the same antigens. Results showed that, regardless of the priming immunogen, animals boosted with protein vaccines had significantly higher antibody titers, including homologous neutralization antibodies (NtAb). After SHIVSF162P4 challenge, significant reduction of mean plasma viral load was observed in all immunization groups. An inverse correlation (Spearman's r = -0.819), p10-fold less than those achieved by animals that were primed DNA or virus vector vaccines. Following intrarectal SHIV162 P4 challenge, all but one animal in each of the protein-DNA or protein-protein prime-boost groups were infected. These results further support the important role of priming in the prime-boost immunization in the generation of protective immunity against primate lentivirus infection.